Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. Отфильтровано по score tier "Top 90+", profit streak "Full 10 yr": 73 match(сбросить фильтры).

#	Тикер	Mkt Cap	Score▼	10Y ROE	Profit Streak	Net Debt/Eq	Gross Margin	Отчёт	FY
1	ResMed Inc RMD · США	$31B	99/100 Элита	20.4%low 15.3%	10 yr+	Net cash	58%	—	FY2025
2	Cadence Design Systems Inc CDNS · США	$94B	97/100 Элита	27.5%low 20.3%	10 yr+	Net cash	88%	—	FY2025
3	Check Point Software Technologies Ltd CHKP · США	$13B	97/100 Элита	26.1%low 20.8%	10 yr+	Net cash	88%	—	FY2025
4	AJ Bell plc AJB · LSE	$2.9B	97/100 Элита	35.9%low 24.8%	10 yr+	Net cash	100%	—	FY2025
5	Adobe Systems Incorporated ADBE · США	$100B	96/100 Элита	33.0%low 15.7%	10 yr+	0.0×	87%	—	FY2025
6	Monster Beverage Corp MNST · США	$94B	96/100 Элита	23.0%low 17.0%	10 yr+	Net cash	58%	—	FY2025
7	F5 Networks Inc FFIV · США	$23B	96/100 Элита	21.7%low 13.0%	10 yr+	Net cash	82%	—	FY2025
8	Federated Investors Inc B FHI · США	$4.6B	96/100 Элита	28.6%low 22.9%	10 yr+	Net cash	68%	—	FY2025
9	Visa Inc. Class A V · США	$684B	95/100 Элита	35.7%low 18.2%	10 yr+	0.1×	81%	—	FY2025
10	Garmin Ltd GRMN · США	$57B	95/100 Элита	17.6%low 14.9%	10 yr+	Net cash	58%	—	FY2025
11	Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A 300760 · Шэньчжэнь	$27B	95/100 Элита	30.1%low 21.4%	10 yr+	Net cash	64%	—	FY2025
12	Snap-On Inc SNA · США	$21B	95/100 Элита	19.5%low 16.4%	10 yr+	Net cash	50%	—	FY2025
13	Manhattan Associates Inc MANH · США	$11B	95/100 Элита	56.1%low 39.9%	10 yr+	Net cash	54%	—	FY2025
14	Jack Henry & Associates Inc JKHY · США	$11B	95/100 Элита	21.7%low 15.4%	10 yr+	Net cash	42%	—	FY2025
15	Paycom Software, Inc. PAYC · США	$7.6B	95/100 Элита	28.8%low 21.9%	10 yr+	Net cash	84%	—	FY2025
16	WD-40 Company WDFC · США	$3.0B	95/100 Элита	36.0%low 30.2%	10 yr+	0.1×	54%	—	FY2025
17	National Beverage Corp FIZZ · США	$3.0B	95/100 Элита	41.0%low 28.7%	10 yr+	Net cash	37%	—	FY2026
18	Automatic Data Processing Inc ADP · США	$106B	94/100 Элита	52.2%low 42.5%	10 yr+	0.2×	47%	—	FY2026
19	Intuit Inc INTU · США	$86B	94/100 Элита	33.7%low 12.6%	10 yr+	0.1×	82%	—	FY2025
20	Fastenal Company FAST · США	$55B	94/100 Элита	31.0%low 25.8%	10 yr+	0.0×	47%	—	FY2025
21	Hansoh Pharmaceutical Group Co Ltd 3692 · Гонконг	$25B	94/100 Элита	26.3%low 11.4%	10 yr+	Net cash	91%	—	FY2025
22	Games Workshop Group PLC GAW · LSE	$8.0B	94/100 Элита	57.4%low 48.6%	10 yr+	Net cash	70%	—	FY2026
23	Rightmove PLC RMV · LSE	$4.4B	94/100 Элита	60.0%low 60.0%	10 yr+	Net cash	100%	—	FY2025
24	Exponent Inc EXPO · США	$3.2B	94/100 Элита	26.7%low 22.8%	10 yr+	Net cash	60%	—	FY2025
25	KLA Corporation KLAC · США	$239B	93/100 Элита	55.9%low 44.2%	10 yr+	0.2×	61%	—	FY2026
26	Kweichow Moutai Co Ltd 600519 · Шанхай	$236B	93/100 Элита	30.8%low 22.9%	10 yr+	Net cash	90%	—	FY2025
27	Hermes International SCA RMS · Париж	$173B	93/100 Элита	24.9%low 18.8%	10 yr+	Net cash	68%	—	FY2025
28	Accenture plc ACN · США	$102B	93/100 Элита	33.4%low 24.6%	10 yr+	Net cash	31%	—	FY2025
29	Infosys Ltd ADR INFY · США	$51B	93/100 Элита	27.5%low 20.1%	10 yr+	Net cash	33%	—	FY2026
30	Corpay Inc CPAY · США	$25B	93/100 Элита	26.1%low 14.7%	10 yr+	0.3×	78%	—	FY2025
31	Nemetschek AG O.N. NEM · XETRA	$7.2B	93/100 Элита	26.3%low 19.4%	10 yr+	0.2×	53%	—	FY2025
32	MarketAxess Holdings Inc MKTX · США	$5.7B	93/100 Элита	25.1%low 19.7%	10 yr+	Net cash	77%	—	FY2025
33	Shenzhen New Industries Biomedical 300832 · Шэньчжэнь	$5.3B	93/100 Элита	23.5%low 17.4%	10 yr+	Net cash	75%	—	FY2025
34	Proya Cosmetics Co Ltd Class A 603605 · Шанхай	$3.3B	93/100 Элита	22.1%low 13.8%	10 yr+	Net cash	66%	—	FY2025
35	ASML Holding NV ADR ASML · США	$626B	92/100 Элита	36.5%low 15.9%	10 yr+	Net cash	49%	—	FY2025
36	Applied Materials Inc AMAT · США	$403B	92/100 Элита	38.9%low 23.8%	10 yr+	Net cash	46%	—	FY2025
37	Roche Holding AG ROG · SW	$326B	92/100 Элита	39.6%low 26.1%	10 yr+	0.5×	72%	—	FY2025
38	NetEase Inc NTES · США	$85B	92/100 Элита	21.6%low 13.4%	10 yr+	Net cash	57%	Углублённое исследование NetEase, Inc.15 июня 2026 г. · Держать	FY2025
39	NetEase Inc 9999 · Гонконг	$85B	92/100 Элита	22.0%low 13.6%	10 yr+	Net cash	57%	—	FY2025
40	Nike Inc NKE · США	$62B	92/100 Элита	33.5%low 19.7%	10 yr+	0.1×	44%	—	FY2026
41	Deutsche Börse AG DB1 · XETRA	$51B	92/100 Элита	18.7%low 16.8%	10 yr+	Net cash	59%	—	FY2025
42	IDEXX Laboratories Inc IDXX · США	$44B	92/100 Элита	58.9%low 55.7%	10 yr+	0.6×	58%	—	FY2025
43	Foshan Haitian Flavouring and Food Co Ltd 603288 · Шанхай	$31B	92/100 Элита	26.3%low 17.0%	10 yr+	Net cash	41%	—	FY2025
44	ANTA Sports Products Ltd 2020 · Гонконг	$28B	92/100 Элита	23.7%low 19.9%	10 yr+	Net cash	57%	—	FY2025
45	Lululemon Athletica Inc. LULU · США	$13B	92/100 Элита	30.2%low 16.2%	10 yr+	Net cash	56%	—	FY2026
46	Brown-Forman Corporation BF-B · США	$13B	92/100 Элита	35.3%low 17.8%	10 yr+	0.5×	62%	—	FY2026
47	SEI Investments Company SEIC · США	$12B	92/100 Элита	27.0%low 21.7%	10 yr+	Net cash	60%	—	FY2025
48	FactSet Research Systems Inc FDS · США	$9.4B	92/100 Элита	40.4%low 27.3%	10 yr+	0.6×	53%	—	FY2025
49	Genpact Limited G · США	$5.1B	92/100 Элита	20.4%low 16.8%	10 yr+	0.2×	36%	—	FY2025
50	Zhejiang Weixing New Building Materials Co Ltd 002372 · Шэньчжэнь	$2.0B	92/100 Элита	23.9%low 15.2%	10 yr+	Net cash	43%	—	FY2025
51	Kainos Group PLC KNOS · LSE	$1.3B	92/100 Элита	34.4%low 25.8%	10 yr+	Net cash	48%	—	FY2026
52	Microsoft Corporation MSFT · США	$3.5T	91/100 Элита	34.6%low 20.0%	10 yr+	0.1×	68%	—	FY2026
53	Edwards Lifesciences Corp EW · США	$50B	91/100 Элита	23.4%low 10.4%	10 yr+	Net cash	76%	—	FY2025
54	Paychex Inc PAYX · США	$42B	91/100 Элита	42.6%low 37.2%	10 yr+	0.9×	71%	—	FY2026
55	Adyen NV ADYEN · Амстердам	$30B	91/100 Элита	23.4%low 18.3%	10 yr+	Net cash	72%	—	FY2025
56	Copart Inc CPRT · США	$27B	91/100 Элита	26.4%low 16.9%	10 yr+	Net cash	45%	—	FY2025
57	Gongniu Group Co Ltd 603195 · Шанхай	$11B	91/100 Элита	36.5%low 24.2%	10 yr+	Net cash	41%	—	FY2025
58	Smith AO Corporation AOS · США	$8.2B	91/100 Элита	23.4%low 13.5%	10 yr+	Net cash	39%	—	FY2025
59	Jiangsu King's Luck Brewery Joint-Stock Co Ltd 603369 · Шанхай	$5.0B	91/100 Элита	19.7%low 15.7%	10 yr+	Net cash	74%	—	FY2025
60	Hubei Jumpcan Pharmaceutical Co Ltd 600566 · Шанхай	$3.4B	91/100 Элита	21.6%low 12.2%	10 yr+	Net cash	83%	—	FY2025
61	MONY Group plc MONY · LSE	$1.3B	91/100 Элита	37.1%low 25.9%	10 yr+	0.1×	66%	—	FY2025
62	Barrett Business Services Inc BBSI · США	$959M	91/100 Элита	24.9%low 17.0%	10 yr+	Net cash	21%	—	FY2025
63	Lam Research Corp LRCX · США	$367B	90/100 Элита	48.3%low 24.3%	10 yr+	Net cash	47%	—	FY2026
64	Cintas Corporation CTAS · США	$82B	90/100 Элита	32.2%low 20.9%	10 yr+	0.5×	47%	—	FY2026
65	Electronic Arts Inc EA · США	$53B	90/100 Элита	18.6%low 10.3%	10 yr+	Net cash	76%	—	FY2026
66	Mettler-Toledo International Inc MTD · США	$29B	90/100 Элита	60.0%low 60.0%	10 yr+	—	57%	—	FY2025
67	Evercore Partners Inc EVR · США	$12B	90/100 Элита	28.4%low 13.7%	10 yr+	Net cash	99%	—	FY2025
68	Orion Oyj B ORNBV · HE	$12B	90/100 Элита	33.1%low 24.4%	10 yr+	0.1×	60%	—	FY2025
69	IMI PLC IMI · LSE	$8.8B	90/100 Элита	24.4%low 21.3%	10 yr+	0.5×	45%	—	FY2025
70	Chemed Corp CHE · США	$7.1B	90/100 Элита	29.2%low 18.2%	10 yr+	0.1×	33%	—	FY2025
71	Howden Joinery Group Plc HWDN · LSE	$5.5B	90/100 Элита	32.1%low 20.5%	10 yr+	0.3×	62%	—	FY2025
72	Ninety One PLC N91 · LSE	$2.7B	90/100 Элита	51.3%low 21.9%	10 yr+	Net cash	64%	—	FY2026
73	Hangzhou Robam Appliances Co Ltd 002508 · Шэньчжэнь	$2.1B	90/100 Элита	19.8%low 10.9%	10 yr+	Net cash	53%	—	FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.